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ABSTRACT OF THE DISSERTATION 
 
Regulation of Motor Proteins by Signaling Kinases 
 
By 
 
Dail Elisse Chapman 
 
Doctor of Philosophy in Biological Sciences 
 
 University of California, Irvine, 2018 
 
Professor Steven P. Gross, Chair 
 
 
 
      Movement is an essential part of life. On the cellular level, movement of intracellular 
components is essential for a cell’s vitality. Most eukaryotic cells are too large to rely on 
diffusion for this, and thus depend on motor proteins. Motor proteins maintain eukaryotic 
cellular organization by actively transporting cargos and controlling positioning of 
subcellular structures on actin and microtubule networks. My research focuses on kinesins 
and dynein, the microtubule-walking motors. Together, these molecules move along 
cytoplasmic microtubule (MT) highways, allowing appropriate cargo positioning and 
delivery. While single-molecule cytoplasmic motor function is relatively well understood, 
there are major gaps in mechanistic understanding of kinesin and dynein regulation in 
cells. My research has detailed two signaling pathways: one likely regulating the kinesin 
motor Eg5, and the other regulating dynein. Specifically, my results show that the kinase 
CK2 activates Eg5 in vitro (Chapter 1). However, the role for CK2 in Eg5 regulation in cells 
is unclear. I also find that the kinase CDK5 along with 14-3-3 and KIAA0528 promote the 
phosphorylation of the dynein co-factor NudEL, and that this phosphorylation is essential 
xiv 
 
for dynein force adaptation in cells (Chapter 2). Finally, I discuss the lab’s most recent work 
in uncovering the cellular function of dynein force adaptation, and put this work into the 
context of the current state of the motors field (Chapter 3). 
 
 
 
 
 
 
 
 
 
1 
 
INTRODUCTION 
 Molecular motors play an important role in active transport of intracellular 
organelles within a cell. Without molecular motors, cells must resort to relying on 
cytoplasmic diffusion, and this would cause such catastrophic delays that much of life as we 
know it could not exist. For perspective, the diffusion constant of a small molecule in water 
is D = 10-5 cm2/sec. Theoretical calculations of the time it would take for a small molecule 
to diffuse 40 cm would take 80 million seconds, or 926 days1. However, should the small 
molecule encounter the viscosity of the cytoplasm (which is roughly 10X more than that of 
water), or other obstacles in the cell, or should the small molecule actually be a much 
bigger entity (like a vesicle), the travel time will take even longer. Molecular motors 
increase this rate immensely, and could actively transport the small molecule 40 cm in one 
day2,3. Just as intracellular transport is important for normal cellular function,  abnormal 
intracellular transport can result in various diseases including cancer4, 
neurodegenerative5,6 and metabolic diseases7–9. Therefore, proper motor protein function 
must be tightly controlled by the cell. 
There are three classes of molecular motors: myosins, kinesins, and dynein. Myosins 
move along smaller actin roads, while kinesins and dynein move along microtubule 
highways10. ATP hydrolysis drives these motors to undergo cyclic conformational changes 
that culminate in the motor stepping along its track10. Much of the biophysics underlying 
such molecular motor mechanics (including run length on the microtubule and force 
production by the motor), and details on associated co-factors have been well studied5,11–16. 
And through the amalgamation of previous work, we have a very thorough understanding 
of molecular motor function in various cell processes17–25.  
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For example, many motors play critical roles in cell division. Specifically, motor 
proteins are important for spindle formation, chromosome alignment, and segregation21. 
By forming bipolar homotetramers, the kinesin protein, Eg5, (studied here) cross-links 
oppositely-directed microtubules and orchestrates proper formation of the mitotic 
spindle26. Mutations in Eg5 can cause mitotic arrest, inhibition of Eg5 decreases tumor 
proliferation27, and because of this, Eg5 is currently under investigation as an anti-cancer 
target27–30.  
On the other hand, processes involving transportation from the cell periphery to the 
cell center involves another motor protein, dynein (dynein-1, MAP1C), studied here11,31. 
Dynein plays roles in vesicular, viral, chromosomal, and nuclear transport, and is essential 
for moving the nucleus in neuronal migration during cerebral development15,32. We 
recently reported that when experiencing opposition to motion, dynein-transported cargos 
can adapt their forces in order to increase group-dynein sustainment of force and 
ultimately overcome the opposition. This was studied by trapping lipid droplet cargos 
(moved by dynein) with an optical trap and determining the force and persistence time 
(the time over which the force is produced) at each lipid droplet’s attempt to escape the 
trap12. This is one example of how motor regulation is dynamic and responsive to cellular 
signals.  
Intracellular transport must be actively tuned by the cell, otherwise all motors 
would be active at all times, resulting in unnecessary motor tug-of-war, potential 
inappropriate local buildups of cargos, and ultimately inefficient transport. Intracellular 
transport is dynamically controlled in order to navigate the complex environment inside a 
cell and insure proper cell function33. For example, in the insulin-secretion pathway whose 
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alteration is implicated in diabetes, GLUT4-containing vesicles must be dynamically and 
appropriately internalized to control sugar uptake, a dynein-dependent process22. In 
fibroblasts, dynein is known to promote directed cell migration by maintaining the position 
of the nucleus in the moving cell (as fibroblast motion is temporarily linked to nuclear 
movement)23. In neurons, kinesin upregulation is important for the delivery of organelles 
along a developing axon24. For example, increased velocity of axonal mitochondria 
transport was found to be important for maintaining mitochondria distribution during 
elongation25. For any of these intracellular transport processes to occur correctly, transport 
must be highly regulated. While we know much of how motors work on the single molecule 
level, and we know many cellular functions of transport, we have an incomplete 
understanding for how intracellular transport is regulated.  Nonetheless, some forms of 
regulation have already been described: auto-inhibition (as described above), interaction 
with other motors34–36, and interaction with cofactors37–41. 
In vitro studies suggested that motor proteins were regulated predominantly by 
auto-inhibitory conformational changes mediated by a head-tail interaction, which is 
subsequently released when the motor is recruited to the cargo42–46. Yet in the context of a 
cell, where motors are frequently cargo-bound, there are many other sources of regulation 
to consider.  
 Cargo-bound motors are also regulated by signaling kinases such as glycogen 
synthase kinase 3 beta (GSK3β), c-Jun N-terminal kinase (JNK), and casein kinase 2 (CK2)47. 
GSK3β phosphorylation of kinesin light chain decreases kinesin-1 binding to cargo; 
similarly, JNK phosphorylation of kinesin-1 heavy chain decreases the motor’s activity by 
inhibiting microtubule binding. Both of these result in inhibited fast axonal transport, such 
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deficiencies are implicated in Alzheimer’s disease47. Our laboratory has identified a novel 
regulatory pathway for kinesin-family proteins40, including the mitotic motor Eg5 
(unpublished), where motors undergo intrinsic inactivation independent of the tail and are 
reactivated by CK2.  
CK2 is a disease-relevant kinase that has been heavily studied due to its myriad 
essential roles in cell division, differentiation, and apoptosis40,48,49. Further, alterations in 
such functions are associated with several cancers, making changes in CK2 potentially 
relevant for cancerous progression. Indeed, CK2 overexpression is observed in many 
cancerous tumors50. However, CK2’s role in motor function has not been significantly 
explored.  
Although CK2 is a pleiotropic kinase with over 300 known substrates 48, CK2’s 
kinase-independent roles have been minimally analyzed; our laboratory has identified that 
CK2 can reactivate Eg5 in vitro independent of its kinase activity (unpublished). Also, 
recent anticancer drugs in clinical trials that act as CK2 kinase inhibitors (by competitive 
binding to CK2’s ATP-binding domain) have been largely ineffective51. And inhibitory drugs 
targeting Eg5 have had mixed results52. This suggests that the current knowledge of Eg5 
inhibition is lacking, and the work presented here in Chapter 1 addresses this problem. 
As evident by the previous discussion, molecular motors carry out a large range of 
functions. To carry out this plethora of roles, kinesins have evolved with increasingly 
diverse intracellular transport in the cell during eukaryotic evolution, (i.e. there is a 
different kinesin motor for different kinesin functions)53. For example, kinesin-1 delivers 
cargo to presynaptic regions of axons, a process vital for synaptic transmission; kinesin-2 is 
the main kinesin involved in intraflagellar transport54. There are also many mitotic 
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kinesins. CENP-E, for example, is involved in establishing the kinetochore54. While fourteen 
different kinesin families have evolved to fulfill each niche, a single dynein motor can carry 
out a similarly diverse set of intracellular transport functions by complexing with different 
cofactors55. Dynein cofactors including dynactin, LIS1, NudE (NDE1), and NudEL (NDEL1)15 
act as sources of regulation. Dynein forms two major complexes: dynein-dynactin-BicD or 
dynein-NudEL-LIS114,56–58. Dynactin is important for increased processivity, and dynein-
dynactin-BicD complexes can travel longer distances16. However, dynactin on its own does 
not bind well to dynein, and so the adaptor family proteins (BicDs, Rabs, Spindly, Hook) are 
needed to activate processive motion and define cargo specificity16. Since much of this has 
been studied in vitro, the next challenge for the molecular motors field is to understand 
how motors function and are regulated within a cellular context. The pathway identified in 
Chapter 2 is one progressive step within this new goal of the field. 
More specifically, we do not understand the signaling pathways that induce dynein 
to complex with either dynactin-BicD2 or NudEL-LIS1, nor do we fully understand the 
capabilities of these complexes. Although there is a report stating that BicD2 can increase a 
single dynein’s force production59, it is known that the NudEL-LIS1 cofactors are important 
for enhanced group force function by improving additivity of single-motor forces12. And 
NudEL and LIS1 and are the important dynein cofactors involved in nuclear movement, a 
function necessitating high dynein force production11. Understanding the function of the 
dynein-NudEL-LIS1 is particularly important as mutations or deletions in the LIS1 gene 
cause neurodevelopmental diseases such as lissencephaly and Miller-Dieker syndrome 
respectively11,60,61. To add even more complexity to the regulation of the dynein-NudEL-
LIS1 core complex, there are other NudEL-interacting regulatory proteins38,62. For example, 
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the signaling kinase CDK5 phosphorylates NudEL in neurons17,19. However, there are 
conflicting studies reporting contrasting effects of phosphorylated NudEL (see Chapter 2: 
Introduction). Most recently, the rerouting of mis-sorted cargo in the axon initial segment 
(AIS) was found to be carried out by phosphoryled NudEL and dynein18. It has been 
assumed63 that CDK5 may not be essential in non-neuronal cells as the main activators for 
CDK5—P35 and P39—are only present in neurons. And so non-neuronal roles for CDK5-
mediated control of dynein remain largely unexplored. However, new evidence of roles for 
CDK564 in non-neuronal cell types support further investigation. 
 14-3-3 is another protein known to regulate phospho-NudEL. If there is a phospho-
regulated dynein-NudEL-LIS1 complex, it could be further modified by 14-3-362. 14-3-3 is 
a family of scaffolding proteins that often protect phosphorylated sites. Clinically, 14-3-3 
deficiency results in worse phenotypes of many dynein-impaired neuronal diseases65–68. 
Therefore, many neurodegenerative and neuropsychiatric disease studies are targeting 14-
3-3. Although dynein impairment characterizes many of these diseases, little is known 
about the function of 14-3-3 in intracellular transport. Interestingly, 14-3-3 supports 
normal dynein complex localization and activity by increasing the strength of interaction 
between dynein and phospho-NudEL38. Further, NudEL can be dephosphorylated by the 
phosphatase PP2A, and 14-3-3 antagonizes PP2A by phosphor-protecting NudEL65.  
Our hypothesis is that the recently described force adaptation of cellular lipid 
droplets12 occurs because CDK5 becomes activated (either by P35/P39 in neurons or some 
other cofactor/s in non-neuronal cells), phophorylates NudEL, thus increasing the affinity 
of NudEL for DIC (dynein intermediate chain), and through increased NudEL-DIC 
interactions, promotes dynein’s utilization of the NudEL-LIS1 system. Further, we 
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hypothesize that these phosphorylation events are protected by 14-3-3. We use lipid 
droplets (LDs) as a model system because their motion and protein makeup is well 
understood, their motion plays a known role in metabolism7, and most importantly, they 
are amenable to force measurements in cells12. While studied in LDs, we further 
hypothesize that this regulatory pathway is generally important for other dynein cargos, 
and thus test it in the context of lysosomes and mitochondria. It is possible that upon some 
trigger (likely the dynein “recognizing” a high-load), there is a switch from dynein-
dynactin-BicD to dynein-NudEL-LIS1. Validation of this hypothesis would be the first 
evidence of dynein complex control within the cell. 
 
Figure 1. A model of dynein complex switching to high utilization of the NudEL-LIS1 system 
 In addition to providing insight into the first identified pathway for force regulation 
in cells, these studies have mechanistic implications in multiple diseases, where transport 
is likely to be important. CDK5 is implicated in Diabetes64,69–72, neurodegenerative 
diseases73, and cancer74, and 14-3-3 is a risk factor in schizophrenia66.  
DIC
NudELLIS1 P
CDK5
14-3-3ε
?
adapted from:
Reddy et a l 2016 Nat Commun
Wynshaw-Boris 2007 Clin Genet
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 Through these studies presented here, we have obtained a better understanding of 
molecular motor regulation in vitro and within the living cell. We suspect that these 
advances in basic biophysics will advance the understanding of the field and ultimately 
inform therapeutic approaches to multiple human diseases where molecular motors and 
their regulators are implicated.  
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CHAPTER 1: Characterizing Eg5 inhibition and regulation by CK2 
Abstract 
 Eg5 is a kinesin that crosslinks oppositely oriented microtubules and ultimately 
establishes formations of the mitotic spindles during mitosis. The Gross lab recently 
discovered that Eg5 inactivated spontaneously (meaning it loses its ability to bind 
microtubules) simply due to aging, that this inactivation could be accelerated due to 
pharmacological inhibition of Eg5, and that both classes of inactivation could be reversed 
by treating the motors in vitro with CK2. We investigated whether this reactivation 
required CK2’s kinase activity and found that it did not: reactivation of Eg5 was kinase-
independent as a kinase-dead CK2 could not reactivate Eg5 motors. CK2’s kinase-
independent roles have been minimally analyzed. Recent drugs that act as CK2 kinase 
inhibitors tested for their effects on cancer have been found to be ineffective in clinical 
trials (by competitive binding to CK2’s ATP-binding domain). And Eg5 inhibitory drugs 
have had mixed results. Importantly, CK2 is over-expressed in many cancers. So, it is 
possible that through aberrant CK2 activity, inactive Eg5 is becoming active, and increasing 
the proliferative state of these cells. Thus, we suggest that CK2 and Eg5’s interaction likely 
counteracts these drugs’ function as potential cancer treatments, explaining their poor 
performances in the clinic. In order to test this hypothesis, I further detailed the 
mechanism of reactivation in vitro and hoped to extend this finding in vivo.  
 
Introduction 
 Many motors play critical roles in cell division. Mutations in the mitotic motor, Eg5, 
can cause mitotic arrest27, and because of this role in spindle function, Eg5 is currently 
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under investigation as an anti-cancer target27–30. In order to develop a new inhibitory 
method, we must further understand the regulation of Eg5. As highlighted in the 
introduction, our laboratory has identified a novel regulatory pathway for kinesin-family 
proteins40, including Eg5 (unpublished), where motors undergo intrinsic inactivation 
independent of the tail and are reactivated by CK2.  
 CK2 is a hetero-tetrameric protein composed of two catalytic subunits  and ’, and 
two regulatory  subunits. There are few known functional differences between the  and 
’ subunits; often CK2 functions with two  subunits without ’75. The cellular levels of 
CK2 are downregulated in some neurodegenerative diseases76, and overexpressed in 
many cancerous tumors50. Although the link between such diseases and transport is not 
well understood, our lab has characterized the reactivation of kinesin-family member 
proteins by CK2-holo in vitro. We began our CK2 regulatory studies with a truncation-
mutant of kinesin-1 (K560: lacking the tail domain) because this is the most well-studied 
motor in the field, and because—since it lacks the tail—it cannot undergo tail-mediated 
auto-inhibition. Published data from our lab shows that when incubated for extended 
periods of time, both full-length endogenous kinesin-1 and K560 become incapable of 
binding MTs, which we refer to as “inactive”40 (see Figure 1 in reference). Since the tail-less 
truncated construct is inactive, this process does not involve the kinesin-1 tail, suggesting a 
new method of inactivation previously unknown to the motor field40 (see Figure 2 in 
reference). Importantly, the CK2 holo enzyme reactivates the inactive kinesin-1; and this 
occurs in vitro with only CK2-holo and K560 present. Furthermore, knocking down CK2 in 
cells reduced the forces powering lipid droplets transport40 (see Figure 6 in reference), 
which is a process dependent on kinesin-1. Thus, CK2 contributes to kinesin function and 
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overall force production in vivo. Considering this and the highly conserved motor domain in 
the kinesin family, we hypothesized that CK2 regulates another kinesin-family member 
protein in cells, Eg5.  
Eg5 is the mitotic motor responsible for the assembly and separation of the mitotic 
spindles20. Inhibition of Eg5 prevents a functional spindle from forming, after which normal 
chromosomal segregation cannot take place, a monoaster forms, and cell cycle checkpoint 
proteins will direct mitotic arrest77. Numerous small molecule anti-cancer drugs have 
targeted Eg5 to try to take advantage of this essential function.  
As a signaling kinase, CK2 has over 300 substrates48. Its kinase ability is thus well 
characterized. However, about 10% of the 518 evolutionarily conserved human kinases 
lack one or more of the three amino acids necessary for a phosphotransfer, but still are 
active regulators78. Our lab has discovered a new and significant kinase-independent, non-
canonical role for the signaling kinase CK2 by studying its regulation of kinesin-1 and Eg5. 
We mapped the phosphorylation site of kinesin-1, mutated it (S520A), and saw comparable 
reactivation by CK240 (see Figure 3f in reference). Furthermore, reactivation of kinesin-1 
by CK2 occurred even in the presence of a known CK2-kinase inhibitor, TCBA, at a 
concentration where kinase activity was clearly obstructed. Thus, based on these results, 
we hypothesized that CK2’s activation of Eg5 in cells is devoid of a phosphotransfer. This 
suggested that CK2 may act independently of its kinase ability to regulate Eg5, a finding 
which I investigate here in Chapter 1. 
The assembly of the mitotic spindle is essential for cell division, and thus small 
molecule cancer drugs have often targeted it. One successful example is paclitaxel (Taxol), 
which binds to tubulin- and stabilizes the mitotic spindle so that the spindles cannot 
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separate. This is arguably the one of the most successful anti-cancer drugs, and it is widely 
used to stabilize malignant tumors79. However, many patients have accrued resistance to 
the drug due to alteration of their microtubule dynamics, including changes in tubulin 
regulation, as well as point mutations in tubulin- that inhibit binding of the drug79. 
Research has since sought out other targets to inhibit the mitotic spindle. Since the motor 
Eg5 is essential for mitotic spindle separation, there has been investigation of anti-Eg5 
drugs. Monastrol, a first generation compound, and ispinesib, a derivative of monastrol 
showed promising results in vitro80. However, these drugs have failed in clinical trials52. 
While this might suggest that the approach is fundamentally flawed, our data suggests 
another possibility: that the monastrol-derived drugs function by increasing the kinetics of 
Eg5 inactivation. If so, the approach is faulty because the cells have a way to reverse the 
Eg5 inactivation via CK2, a protein that is upregulated in most cancers. Thus, there is a 
need for a drug that targets Eg5 through a different mechanism, either by blocking the Eg5-
CK2 interaction, or by inactivating Eg5 by a non-endogenous pathway that cannot be easily 
reversed by CK2. One appealing candidate is a new natural product, Terpendole E, which 
was recently reported to inhibit Eg529; Terpendole E binds to a different and currently 
unknown locus on Eg5, distinct from the other monastrol, and monastrol-derivative 
inhibitors. I investigate the effects of Terpendole E and its derivative small molecule 
inhibitor, Emindole SB, in this Chapter. 
To summarize, I aimed to determine CK2 relevance to Eg5 function in vivo by: 1) 
detailing the mechanism of reactivation of Eg5 by CK2 in vitro via microtubule 
sedimentation experiments and microtubule gliding assays with purified Eg5 motors, and 
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2) extending these in vitro findings to the cell by analyzing cell proliferation in various 
formats of CK2 inhibition.  
 
Results 
     CK2 subunits  and ’ together reactivate Eg5 in vitro 
 In order to determine the activity of a sample of molecular motors, one can conduct 
a microtubule sedimentation experiment. Only active motors bind microtubules; so, to 
separate the active motors from the inactive motors, one can incubate the sample of motors 
with microtubules, and use high-speed centrifugation to pellet the microtubules along with 
the fraction of active motors. To determine if CK2 affected the ability of inactivated Eg5 to 
bind microtubules, I conducted microtubule sedimentation experiments with various 
subunits of the CK2 holo enzyme in order to determine which subunit(s) was/were 
responsible for the reactivation of Eg5. I found that the CK2 holo enzyme could reactivate 
Eg5 as evidenced by greater amounts of Eg5 detected in the microtubules fraction of the 
sedimentation experiment. Interestingly, a combination of CK2 and CK2’ were also able 
to reactivate Eg5 to a similar degree as the CK2 holo enzyme. This suggested that the 
regulatory subunit, CK2, is not needed for Eg5 reactivation. However, when testing CK2- 
or CK2-’ alone, they were not able to reactivate Eg5 (Figure 1.1), suggesting that CK2- 
and CK2-’ work together to reactivate inactive Eg5 motors.  
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Figure 1.1. Increased co-sedimentation of Eg5 motors with microtubules with CK2 
Purified Eg5 motors were inactivated on ice and then submitted to microtubule sedimentation experiments with various 
CK2 subunits. WB analysis (left) and quantification of WBs (right) shows of the microtubule sediment showed a 
significant increase in the amount of Eg5 in CK2-holo and CK2 + ’ samples, but not in samples with no CK2, , or ’ 
alone.  
To support this data, our collaborators in Steve Rosenfeld’s lab at the Cleveland 
Clinic performed TMR (tetramethylrhodamine) dimerization experiments to look at the 
kinetics of Eg5 reactivation with the CK2 holo enzyme and CK2-’. They used purified TMR-
tagged recombinant Eg5 motors; when the Eg5 motor neck linker docks (i.e. the motor is in 
its inactive conformation), the TMR-fluorescence quenches. When the Eg5 motor is in its 
active form, the TMRs are too far apart, and they observe fluorescence. By measuring the 
amount of fluorescence in the presence of either CK2 holo enzyme or CK2’, they can 
determine the amount of active Eg5 motors. They found that the CK2 holo enzyme was able 
to reactive Eg5 (Figure 1.2), which supported our microtubule sedimentation experiments 
(Figure 1.1). To our surprise, our collaborators found that the presence of CK2-’ causes 
more Eg5 neck-linker undocking than the CK2 holo enzyme (Figure 1.2). 
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0
1
2
3
4
5
aa’
N
o
rm
a
liz
e
d
I˚n
te
n
s
it
y
No˚CK2 a + a’ CK2˚Holo
*
15 
 
 
Figure 1.2. CK2’ acts differently than CK2 holo enzyme in Eg5 reactivation. 
Eg5 labeled with TMR at sites engineered to detect NL docking via TMR dimerization, was thawed and diluted to 0.1μM 
and incubated at room temperature for 20 mins. After the 20 minute incubation, CK2 (NEB) or CK2-alpha (Millipore) was 
added to a final concentration of 0.4μM. Time-resolved fluorescent waveforms were acquired every 30 seconds for 100 
minutes. Data is plotted as total fluorescence from samples containing CK2 (red) or CK2’ (blue). 
Eg5 inhibitors have various efficacies in vitro 
Now that we had a suggestion of the mechanism of action of CK2, I wanted to test 
different Eg5 inhibitors in vitro via microtubule gliding experiments. As a proof of principle, 
I first tested previously studied Eg5 inhibitors, monastrol and ispinesib, and indeed saw 
that increasing concentrations of these two inhibitors decreased the percentage of 
microtubules gliding along the microscope slide (Figure 1.3a, b). This suggests that as the 
concentration of the inhibitor increases, there are less active Eg5 motors able to bind and 
walk along microtubules. I then tested two members of a new class of inhibitors: 
Terpendole E and Emindole SB created by Sergi Pronin’s lab at University of California 
Irvine. Findings from this experiment suggested that Terpendole E but not Emindole SB 
inhibited Eg5 significantly (Figure 1.3c-f). Unfortunately, no new developments in this 
project can be reported here. 
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Figure 1.3. Eg5 inhibitors have different efficacies. Various concentration of four Eg5 inhibitors were tested in 
microtubule gliding experiments. Monastrol (a), ispinesib (b), Terpendole E (c) all showed significant Eg5 inhibition. 
However, Emindole SB (d) did not significantly inhibt Eg5. Chemical structures of Terpendole E (e) and Emindole SB (f) 
are shown. Quantified data represent mean  s.e.m.  
     CK2 kinase activity is important for cell proliferation  
I moved on to determine the cellular importance of CK2- (and CK2-’) reactivation 
of Eg5 in vitro. Since Eg5 is necessary for spindle formation and cell proliferation20,21, we 
conducted CK2- knockdowns and cell proliferation assays in order to inhibit the ability of 
CK2- to reactivate Eg5 in vivo. Indeed, cell proliferation was decreased in the CK2- 
knockdown cells (Figure 1.4). Since we had determined that CK2- can reactivate kinesin-
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1 independent of its kinase ability, we wanted to repeat our cell proliferation assays with 
the CK2 kinase inhibitor, CX4945. If CK2 regulates Eg5 in vivo, and this regulation is 
independent of CK2’s kinase activity (as seen in our in vitro data), I would expect to see a 
slightly increased proliferation rate in these cells as compared to the CK2- knockdown 
cells. This is because in the cells treated with CX4945, CK2’s ability to regulate Eg5 should 
still be intact. However, this is not what we observed. Treatment with CX4945 shows 
similar decrease in cell proliferation as the CK2- knockdown cells as compared to the 
control cells which were treated with either transfection reagent or vehicle (DMSO) 
(Figure 1.4).  
 
Figure 1.4. CK2 knockdown and kinase inhibition decrease cell proliferation. Knocking down CK2 decreases cell 
proliferation. Treatment with CK2 kinase inhibitor, CX4945, also shows a similar decrease in cell proliferation compared 
to the control.  
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Discussion 
Upon starting my dissertation work, the lab had recently published a paper stating 
that CK2 could reactivate kinesin-141. It was important to further study this reactivation by 
extending it to other kinesins, including Eg5, uncover the mechanism of reactivation, and 
determine if this motor control pathway was important in cells. To start, I determined that 
certain CK2 subunits can reactivate Eg5 motors in vitro. Specifically, CK2- and CK2-’ 
together, but not CK2- or CK2-’ alone, could reactivate Eg5 motors as evidenced by the 
increased amount of Eg5 motors in the microtubule sediment when CK2- and CK2-’ 
were incubated together with Eg5 (Figure 1.1). This allowed us to determine which 
subunit was important and focus our knockdowns on that particular subunit in vivo. 
Interestingly, it also suggests that the catalytic subunit, CK2-, is not enough to reactivate 
Eg5. Somehow, CK2-’ is needed. The kinetic experiments from our collaborators in Steve 
Rosenfeld’s lab provided more information, suggesting that CK2-’ is responsible for Eg5 
neck-linker undocking. Since in these experiments, amount of undocked motors is relative 
to the amount of fluorescence, incubation with CK2-’ caused more undocking than the 
CK2-holo enzyme (Figure 1.2). However, this must not be enough to fully reactivate the 
motor as there was no increase in amount of active motors found in the microtubule 
sedimentation samples containing CK2-’ alone. It is possible that there is a second 
conformational change for which CK2- is needed. Therefore, it likely takes both CK2- 
and CK2-’ to change the conformation of Eg5 into the completely active form40,41.  
However, our data are not detailed enough to prove this completely.  
Since aberrant CK2 and Eg5 activity is characteristic of many cancers50,81, and we 
had evidence suggesting a kinase-independent pathway that could function in 
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carcinogenesis, we wanted to study new inhibitors of Eg5 developed by Sergi Pronin’s lab. 
Perhaps one of them functions to block the reactivation of Eg5 by CK2. To start, we tested 
Terpendole E and Emindole SB in microtubule gliding assays. Indeed, Terpendole E 
inhibited Eg5 sufficiently (Figure 1.3c); however Emindole SB did not shown inhibition 
(Figure 1.3d). Since Terpendole E was developed to interact with a different locus on Eg5, 
we considered it might possibly inhibit the reactivation by CK2 and had plans to further 
study this promising inhibitor. As Emindole SB was newly synthesized, our collaborators in 
the Pronin lab suggested that there might be impurities that were altering the efficacy of 
the small molecule inhibitor. While they worked to optimize these small molecules 
structures and synthesis, we worked to determine if the reactivation of Eg5 by CK2 is 
important in cells.  
Since it is well known that both CK2 and Eg5 have important functions in cell 
proliferation28–30,82, we decided to use cell proliferation as a read-out of the importance of 
this pathway. We thought that if we knocked down CK2-, that would limit its ability to 
reactivate Eg5 (as well as its function in other cellular pathways), and that this would likely 
decrease cell proliferation. Indeed, this is what we saw in the CK2- knockdown cells 
(Figure 1.4). We then hypothesized if Eg5 reactivation by CK2- is an important pathway 
in cells, then inhibiting the kinase ability of CK2 (by treatment with the inhibitor, CX4945) 
would not show as much of a decrease in cell proliferation (compared to the control cells) 
since this pathway would remain intact. Yet, the cells treated with CX4945 show similarly 
limited cell proliferation to the CK2- knockdown, suggesting that CK2’s ability to 
reactivate Eg5 motors is likely not important to cell proliferation (Figure 1.4). Although we 
had characterized a possible interaction in vitro, our data suggested that this pathway is 
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possibly not important in cells (or it is important, but not for cell proliferation). Because we 
found evidence that the reactivation of Eg5 by CK2 is not important in vivo, we moved on to 
study the regulation of dynein.  
 
Materials and Methods 
Microtubule Sedimentation: Purified Eg5 (a gracious gift from the Rosenfeld Lab, 150nM) 
was incubated for 2 hours on ice in order to inactivate the motors. In the meantime, tubulin 
(6.6 mg/mL) was polymerized by incubating microtubules in microtubule growing buffer 
(100mM PIPES, 1mM MgSO4, 2mM EGTA, 0.3mM GTP, 20µM Taxol) at 37C for 20 mins to 
make microtubules (MT). Then, the motors were incubated with assay buffer (5M MT, 
80mM PIPES, pH 6.9, 5mM potassium acetate, 4mM AMP-PNP (EMD)) with recombinant 
CK2 (holoenzyme or subunits as indicated, up to 250nM, holo-New England Biolabs, /’ 
subunits Millipore) in 20µl reaction buffer (20mM tris–HCl pH 7.5, 50mM KCl, 10mM 
MgCl2, 0.5mM EGTA, plus 500µM ATP) at 30 °C for 40min (optimal for CK2 kinase activity). 
Reactions from which CK2 had been omitted served as controls.  
In vitro CK2 re-activation. After motor inactivation, 10µl each of the kinesin samples are 
identically transferred to two sets of new Eppendorf tubes. For one set, 10µl CK2 reaction 
buffer (Millipore) was added. For the second set containing identical kinesin samples, 10µl 
CK2 (500nM) was added, followed by a 2 hour incubation at room temperature, then 
assayed for active motor fraction via microtubule pulldown.  
Microtubule affinity pulldown. Kinesin with indicated amounts of CK2 holoenzyme or 
subunit and indicated incubation conditions were incubated with the polymerized 
microtubule-containing assay buffer for 15 min at room temperature (RT). The reaction 
21 
 
was centrifuged in a TLS55 rotor for 10min at 170,000g at 25 °C. The resulting microtubule 
pellet was dissolved in 30µl 1X reducing SDS sample buffer, separated by SDS–PAGE, and 
analyzed by immunoblot. Experiments were conducted in triplicate. Previously described40. 
TMR Dimerization Fluorescence Imaging: previously described83.  
Microtubule Gliding: clean slides were silanized by incubating slides in a 0.05% DSS 
solution in TCE for 1 hour. Slides were then transferred to various methanol baths and 
sonicated for 5, 10, 15, and 30 minutes. Slides were dried with clean nitrogen gas. Tubulin 
(30% rhodamine-tubulin (Cytoskeleton Inc, T331) and 70% nonfluorescent tubulin) was 
polymerized as described above, and kept in the dark during the polymerization 
incubation. A flow chamber was constructed with a microscope slide and a silanized slide 
separated by double-sided tape. Penta-His antibody (200µg/mL, Qiagen) was diluted to 
20µg/mL in assay buffer (2.5mL antibody, 80mM PIPES, 4mM MgSO4, 1mM EGTA) and 
flown through the chamber for 5 mins. The surface was then blocked with CDB5.5 solution 
(35mM PIPES, 5mM MgSO4, 1mM EGTA, 0.5mM EDTA, plus 5.55mg/mL of casein) for 5 
mins. Next, Eg5 motors were added in 80 mM PIPES (pH 6.9), 50mM potassium acetate, 
4mM MgSO4, 1mM DTT, 1mM EGTA, 10μM taxol, 1 mg/mL casein and incubated for 5 min 
to bind the motors specifically to the antibodies. Finally, 1μL of fluorescent MTs was added 
in 50μL of motility buffer with 0.6 mM ATP and an oxygen-scavenging system (250 μg/mL 
glucose oxidase, 30 μg/mL catalase, 4.5 mg/mL glucose). MT gliding was monitored using 
an inverted microscope (TE2000; Nikon) with a 100X objective (NA = 1.49). Fluorescence 
images were acquired at 11.8 frame/s (FPS) using an EMCCD camera (Quantem 512SC; 
Photometrics; 512 × 512 imaging pixels) and μ-Manager software; one pixel corresponded 
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to 60 nm. Movies were composed of approximately 500 images. Percent of gliding 
microtubules was calculated. Previously described84.  
Cell Proliferation: Mycoplasma-free COS-1 cells (obtained from ATCC) were grown in 
DMEM (Genesee) supplemented with 10% fetal bovine serum and 1% Pen-Strep at 37 C in 
5% CO2. 1000 cells were plated in each well of a 96-well tissue culture treated plate. A 
calibration curve of cells was plated with 500, 1000, 2000, 4000, and 8000 cells. HiPerfect 
(Qiagen) was used according to manufacturer’s instructions. CK2 was knocked down by 
diluting each CK2 siRNA (Qiagen SI02660497 and SCBT sc-29918) to 300nM final 
concentration. Cells were incubated for 24 hours. Cell count was analyzed on a plate reader 
with the CCK-8 Kit (Sigma-Aldrich) according to manufacturer’s instructions. The plate was 
read every 24 hours for 5 days.  Absorbance values were used to calculate the number of 
cells in each well at each time point. 
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CHAPTER 2: Regulation of in vivo dynein force production by CDK5, 14-3-3, and 
KIAA0528 
Abstract 
Single-molecule cytoplasmic dynein function is relatively well understood, but there 
are major gaps in mechanistic understanding of dynein regulation in cells. We previously 
reported a novel mode of dynein regulation, force adaptation, where lipid droplets adapt to 
opposition to motion by increasing the duration and magnitude of force production, and 
found LIS1 and NudE/NudEL to be essential. Since adaptation reflects dynamically 
increasing utilization of NudE/NudEL-LIS1, we here hypothesize that CDK5-mediated 
NudEL phosphorylation controls utilization of NudEL, and through this, makes force 
adaptation possible. Here, we report that CDK5, the phospho-protector 14-3-3, and the 
newly studied CDK5 cofactor KIAA0528 are all essential for dynein force adaptation. We 
extend this in vivo regulatory pathway to lysosomes and mitochondria. Ultimately, we 
show that dynein force adaptation can control the severity of lysosomal tug-of-wars among 
other important intracellular transport functions involving high force. 
 
Introduction 
Cytoplasmic dynein (dynein-1, MAP1C) is essential for intracellular transport of 
organelles and other cargos towards the cell’s nucleus31,11. Together with the opposite 
directed plus-end kinesin family of motors, these molecules move along cytoplasmic 
microtubule (MT) highways, allowing appropriate cargo positioning and delivery.  
Dynein plays roles in vesicular, viral, chromosomal and nuclear transport, and is 
essential for neuronal migration during cerebral development32,15. Due to this diversity of 
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roles, it is highly regulated, frequently via regulatory cofactors including dynactin, LIS1, 
NudE (NDE1), and NudEL (NDEL1)15. Dynein forms two major complexes: with dynactin or 
with NudEL-LIS114,56–58. Dynactin is important for increased processivity, and dynein-
dynactin-BicD complexes can travel longer distances16. Deletions in the LIS1 gene cause 
Miller-Dieker syndrome61, presumably because its presence enhances additivity of single-
motor forces12, and thus facilitates dynein’s high-load function, which is important for the 
nuclear migration11,60 underlying neuronal migration; through utilization of the NudEL-
LIS1 system, neurites can undergo cell migration: a leading extension of the soma, followed 
by the discontinuous movement of the largest organelle, the nucleus. As the nucleus 
progresses, the rest of the cell follows. It has been shown that LIS1 and dynein together are 
important for extension and soma movement60. Furthermore, NudEL tethers LIS1 to 
dynein, and helps regulate the dynein-LIS1 interaction. It is unclear how these two 
complexes (dynein-dynactin or dynein-NudEL-LIS1) coordinate to regulate dynein. They 
may or may not function simultaneously: they share an either-or interaction site on the 
dynein intermediate chain (DIC)56, but LIS1 associates with moving dynein-dynactin-BicD2 
complexes39. One model is that the two complexes multiplex, or trade off binding with 
dynein, but how this might be regulated is not understood.  
In addition to the dynein-NudEL-LIS1 core complex, there are other NudEL-
interacting proteins that provide further regulation38,62. In neurons, the signaling kinase 
CDK5 phosphorylates NudEL19,17. However, the mechanistic implications of this 
phosphorylation are controversial, with respect to the effect on microtubule dependent 
cargo transport in axons. Klinman et al suggest that NudEL phosphorylation by CDK5 
increases dynein-NudEL-LIS1 affinity and locks dynein in a nucleotide-bound state that 
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decreases processive motion of various dynein cargos17. In contrast, Pandey et al suggest 
that CDK5 phosphorylation of NudEL leads to increased dynein activity by promoting a 
high affinity dynein-NudEL-LIS1 complex, which then increases transport by dynein19. 
Most recently, CDK5 phosphorylation of NudEL was found to be critical for rerouting mis-
sorted dendritic cargo out of the axon initial segment (AIS), a dynein-dependent process18. 
Any role for CDK5-mediated control of dynein in non-neuronal cells is unknown. Because 
the main activators for CDK5—P35 and P39—are only present in neurons, it has been 
assumed63 that CDK5 may not be important in non-neuronal cells. However, new evidence 
for pleiotropic non-neuronal roles for CDK564 supports a re-evaluation of this assumption.  
Assuming a phospho-regulated dynein-NudEL-LIS1 complex, it could be further 
modified by 14-3-362, since clinically, many dynein-related neuronal diseases are made 
worse by 14-3-3 impairment. For instance, decreased 14-3-3 protein levels correlate 
with a worsened lissencephaly phenotype in LIS1-deficient patients65. Further, 14-3-3 
mRNA expression levels are decreased in the prefrontal cortex of schizophrenic and 
bipolar patients66,67. Lewy bodies, abnormal protein aggregates found in Parkinson’s 
disease nerve cells, contain 14-3-368. Thus, 14-3-3 is an actively studied target in 
neurodegenerative and neuropsychiatric diseases. However, little is known about its 
function in intracellular transport. Interestingly, 14-3-3 interacts strongly with phospho-
NudEL to promote normal dynein complex localization and activity38. Finally, NudEL can be 
dephosphorylated by the phosphatase PP2A, and 14-3-3 protects phospho-NudEL by 
sterically inhibiting PP2A access to the phosphorylation sites65.  
All of this leads to the model—relevant in both non-neuronal and neuronal cells—
tested in this work. Our hypothesis is that the recently described force adaptation of 
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cellular lipid droplets12 occurs because CDK5 becomes activated, phophorylates NudEL, 
thus increasing the affinity of NudEL for DIC, and through increased NudEL-DIC 
interactions, promotes dynein’s utilization of the NudEL-LIS1 system. Further, we 
hypothesize that NudEL phosphorylation is protected by 14-3-3 (Figure 1). We use lipid 
droplets (LDs) as a model system because their motion and protein makeup is well 
understood, their motion plays a known role in metabolism7, and most importantly, they 
are amenable to force measurements in cells12. While studied in LDs, we further 
hypothesize that this regulatory pathway is generally important for other dynein cargos, 
and thus test it in the context of lysosomes and mitochondria.  
In addition to providing insight into the first identified pathway for force regulation 
in cells, these studies have mechanistic implications in multiple diseases, where transport 
is likely to be important. CDK5 is implicated in Diabetes64,69–72, neurodegenerative 
diseases73 and cancer74, and 14-3-3 is an important risk factor in schizophrenia66. 
 
Results 
     Force adaptation in wildtype COS-1 cells 
We previously showed that under load, both forces and persistence times (the time 
over which the force is maintained) in dynein-driven LD cargos increase at each attempt12; 
the increase is typically first apparent in attempt two or three, and statistically significant 
by attempt four or five (Figure 2.1, Supplementary Figure 2.8); the data here reflect new 
unpublished measurements, made concurrently with the other studies described in this 
manuscript. This trend occurs when measurements are made both in unperturbed 
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wildtype cells and in control cells treated with transfection reagent (Supplementary 
Figure 2.1). 
 
Figure 2.1.  Minus-end forces and persistence times increase when dynein-driven LD cargo are under load 
Average peak forces for minus-end moving LDs show slight increase in the control  background (a). Average persistence 
times for dynein-driven LDs show significant increase in WT background (b). Quantified data represent the mean  s.e.m. 
of n = 5 independent experiments. One-tailed t-test *P <0.05, **P < 0.01, ***P < 0.001 
     CDK5 is essential for dynein force adaptation 
CDK5 phosphorylation of NudEL has been shown by three separate groups 63,37,85,86. 
Thus, we explored the possibility that CDK5 phosphorylation of NudEL is important for 
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dynein force adaptation. We knocked down endogenous CDK5 (Figure 2.2e) and under 
such conditions found that dynein force production does not increase at each attempt as for 
the wildtype, but instead forces and persistence times decreased with subsequent attempts 
(Figure 2.2a, b, Supplementary Figure 2.8). The same phenotype was observed when we 
blocked CDK5 activity by overexpressing a previously characterized dominant-negative 
CDK5 construct (CDK5dn, containing an R33T mutation)19 (Figure 2.2c, d, f, 
Supplementary Figure 2.5, Supplementary Figure 2.8). Neither CDK5 knockdown nor 
CDK5dn overexpression altered plus-end forces (Supplementary Figure 2.2). Thus, 
inhibiting CDK5’s kinase activity coincides with alteration of dynein force adaptation in 
cells, where forces and force durations decrease rather than increase. After conducting 
immunolocalization experiments on purified LDs, we found that CDK5 was indeed present 
on the LDs, supporting this CDK5 regulatory function (Figure 2.3, Supplementary Figure 
2.6).  
     14-3-3 is essential for dynein force adaptation 
We next examined 14-3-3, since in a neuronal context, it was previously reported 
to protect phospho-NudEL62. Consistent with a potential role in LD function, we found that 
14-3-3 was present on purified LDs (Figure 2.3, Supplementary Figure 2.6). When we 
knocked down 14-3-3 (Figure 2.4, Supplementary Figure 2.5), the result was 
reminiscent of that observed for the CDK5 knockdown, but less severe: in contrast to wild-
type behavior, neither forces nor persistence times increased at successive attempts 
(Figure 2.4a, b, Supplementary Figure 2.8), though they did not decrease as was the case 
for CDK5 knockdown. Again, no obvious effect was observed on plus-end force production 
(Supplementary Figure 2.2). 
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     KIAA0528 is a CDK5 co-factor necessary for force adaptation in COS-1 cells 
Since CDK5 activity is highly characterized in neuronal cell types, but less is known 
about its function in non-neuronal cells, we became interested in factors contributing to its 
non-neuronal activity. Additionally, as CDK5 is a known key regulator for the dynein 
motor19,17,18, further characterization of CDK5 interactors could lead to novel dynein 
regulatory mechanisms. We searched the CDK5 interactome via recent proteomic analysis 
of CDK5-associated protein complexes, and prioritized candidates that are known to have 
microtubule-related cellular functions. This led us to KIAA0528 for multiple reasons: 1) it 
was identified as the top binding protein87, 2) this interaction was validated with anti-KIAA 
and anti-CDK5 immunoprecipitations87, and 3) KIAA0528 is involved in GLUT4 transport8, 
a motor-dependent process relevant in diabetes. KIAA0528 is also potentially involved in 
cancer metastasis as it plays roles in cell proliferation and migration88. However, as a newly 
studied protein, its function is relatively unknown. As KIAA0528’s interaction with CDK5 
had been confirmed via multiple approaches87,  it seemed likely that if present, it might 
alter CDK5 function. We found KIAA0528 on purified LDs in COS-1 cells (Figure 2.3, 
Supplementary Figure 2.6), positioning it to contribute to LD transport. We then knocked 
down KIAA0528 (Figure 2.5c, Supplementary Figure 2.5) and conducted force 
measurement experiments in this background. The effect of loss of KIAA0528 was similar 
to that of 14-3-3: adaptation was eliminated, and neither forces nor persistence times 
changed (Figure 2.5, Supplementary Figure 2.8). As for the CDK5 and 14-3-3 
knockdown backgrounds, the perturbation of KIAA0528 function did not alter plus-end 
force production (Supplementary Figure 2.2).  
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Figure 2.2. CDK5 is essential for dynein force adaptation in COS-1 cells 
Average peak forces for minus-end moving LDs decrease at successive attempts in CDK5 knockdown background (a) and 
CDK5dn overexpression background (c). Average persistence times for dynein-driven LDs show a significant decrease in 
CDK5 knockdown background (b) and CDK5dn overexpression background (d). CDK5 knockdown was >90% effective 
(e), and CDK5dn overexpression was successful (over 15X increase in expression of control) (f). Quantified data represent 
the mean  s.e.m. of n = 5 independent experiments. One-tailed t-test *P <0.05, **P < 0.01 
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Figure 2.3. CDK5, 14-3-3, and KIAA0528 are found on lipid droplet (LD) cargo 
Purified LDs were probed with antibodies against CDK5, 14-3-3, KIAA0528, and GFP (negative control) (b); shown are 
the percentage of LDs that had detectable immunofluorescence signal. Quantified data represent the mean  s.e.m. of n = 2 
independent experiments. Test of proportions *P <0.05, ***P < 0.001, ****P < 0.0001 
 
Figure 2.4. 14-3-3 is essential for dynein force adaptation in COS-1 cells 
Average minus-end peak forces (a) and persistence times (b) at each attempt do not increase in the 14-3-3 knockdown 
background. 14-3-3 knockdown was >80% effective (c) Quantified data represent the mean  s.e.m. of n = 4 independent 
experiments. One-tailed t-tests results were not significant (ns) 
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Figure 2.5. KIAA0528 is essential for dynein force adaptation in COS-1 cells 
Neither average minus-end peak forces (a) nor persistence times (b) at each attempt increase in the KIAA0528 
knockdown background. KIAA0528 knockdown was >99% effective (c) Quantified data represent the mean  s.e.m. of n = 
4 independent experiments. One-tailed t-tests results were not significant (ns) 
     Confirmation of the functional importance of NudEL phosphorylation.  
NudEL and its sister protein NudE contain 55% identical protein sequence, but 
recent knockout mice of the respective proteins have suggested that the two might have 
slightly different functions89,90. Specifically, NudE KO mice are viable, but have smaller 
brains than control mice89; however NudEL KO mice are embryonic lethal90. If dynein is 
unable to adapt in the specific knockdown of NudEL, perhaps this suggests that force 
adaptation is in fact an essential dynein function. (However, we did not test force 
adaptation in a NudE knockdown background.) We previously reported12 that dual knock-
down of NudE and NudEL eliminated force adaptation. Here, we found that knocking down 
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NudEL alone also abolished force adaptation (KD in Figure 2.6c, d, Supplementary Figure 
2.8); while we suspect that our NudEL knockdown is specific to NudEL as none of the four 
siRNA target sequences used were found in the NudE mRNA sequence, our western blot 
analysis of NudE levels remains inconclusive (data not shown). Thus, to confirm directly 
the importance of NudEL phosphorylation, we wanted to test for function in a background 
with modified NudEL phosphosites. Because CDK5 and 14-3-3 are reported to affect 
NudEL phosphorylation in a neuronal context, and KIAA0528 is a CDK5-interacting protein 
potentially contributing to CDK5-mediated phosphorylation, we hypothesized that the 
overall impairment in force adaptation in all of these backgrounds reflects a loss of CDK5-
mediated NudEL phosphorylation. The CDK5 phosphosites on NudEL had previously been 
determined63 (and confirmed in multiple other publications37,85,86), so to directly assess the 
ramifications of such phosphorylation events, we carried out force measurement 
experiments after knocking down endogenous NudEL and replacing it with either NudEL-
GFP-wild-type (KDandR-WT), NudEL-GFP-phospho-null (KDandR-null), or NudEL-GFP-
phospho-mimetic (KDandR-mim) variants. Because NudEL dosage matters, the 
replacement constructs were expressed at levels comparable to endogenous NudEL 
expression (Figure 2.6e, Supplementary Figure 2.5), and all mutants were expressed at 
similar levels to each other.  
Importantly, under KDandR-WT conditions, we found that both forces and 
persistence times increased at successive attempts, similar to the control condition (Figure  
2.6a, b, Supplementary Figure 2.8). Since force adaptation was lost due to the NudEL KD 
(KD in Figure 2.6c, d, Supplementary Figure 2.8), this rescue showed not only that our 
rescue construct was indeed functional, but also that the previous loss of force adaptation 
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had indeed been due to loss of NudEL function (since the knockdown reagents used in both 
sets of experiments were identical, and the only difference was the presence or absence of 
the KD-resistant NudEL rescue construct).  Under KDandR-null conditions, force adaptation 
was impaired: forces did not increase, and persistence times decreased significantly, 
similar to what occurred in the CDK5-KD background (KDandR-null in Figure 2.6c, d, 
Supplementary Figure 2.8). However, under KDandR-mim conditions, we partly rescued 
force adaptation: forces did not significantly increase, but persistence times increased by 
attempts 4 and 5 (KDandR-mim in Figure 2.6c, d, Supplementary Figure 2.8). 
Importantly, our data indicate that the phospho-null rescue construct is functional: 
replacing with the phospho-null mutant decreases persistence times relative to the KD 
alone. Further, combined, the results confirmed the importance of the phospho-sites, but 
modify our initial model that CDK5-mediated phosphorylation alone accounted for force 
adaptation (see discussion). 
     The CDK5 pathway is important for other dynein cargos 
Having extensively characterized the role of CDK5, 14-3-3, and KIAA0528 in dynein 
force adaptation with LD cargos, we wondered whether this regulatory pathway was 
important for other dynein cargos. We thus examined lysosomes and mitochondria. First, 
we conducted knockdown experiments and visualized the cargos’ spatial distribution in 
each case. Loss of NudEL affected the distribution of both cargos (Figure 2.7, 
Supplementary Figure 2.7), confirming that NudEL contributes to their positioning. 
Further, loss of CDK5 activity altered the distribution of both lysosomes and mitochondria 
in a manner quantitatively similar to the effects of loss of NudEL for both classes of cargos. 
Loss of 14-3-3 also had a comparable effect to NudEL and CDK5 knockdowns (Figure 2.7, 
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Supplementary Figure 2.7). The lysosomal redistribution may reflect a feedback effect: in 
the wild-type, plus-end runs and minus-end runs are slightly longer than in the CDK5 
knockdown background (Supplementary Figure 2.3c, d), possibly contributing to 
increased lysosomal dispersion. While we do not fully understand why there is a difference 
in the lysosome and mitochondrial distributions upon force adaptation impairment, the 
fact that there is, and that it is the same as what occurs for the NudEL knockdown, suggests 
that overall, NudEL utilization is being regulated by CDK5 and 14-3-3, and that this, 
among other things, contributes to positioning of multiple cargos. Intriguingly, there was a 
differential effect due to the loss of KIAA0528: its loss had no effect on lysosomes, but 
altered mitochondrial distributions similarly to CDK5 and 14-3-3 loss. Thus, we concluded 
that as for the LDs, KIAA0528 is required for NudEL-CDK5-14-3-3 utilization in the 
mitochondria, but the lysosomal NudEL-CDK5-14-3-3 pathway functions without it.  
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Figure 2.6. NudEL knockdown and replacement force profiles depends on NudEL phospho-state 
Average minus-end peak forces (a) and persistence times (b) for control and NudEL knockdown and NudEL-WT 
replacement backgrounds. Average minus-end peak forces (c) and persistence times (d) for NudEL knockdown and 
NudEL knockdown and phospho-null and phospho-mimetic replacement backgrounds. Average endogenous NudEL 
(Endo NudEL) knockdown was 70%, average exogenous replacement (GFP-NudEL, band seen in NudEL KDandR WT lane) 
was 102% wildtype NudEL levels (left). WB probed for GFP found replacement with WT, null, and mimetic mutants 
resulted in similar expression levels (right). (e) Quantified data represent the mean  s.e.m. of n  3 independent 
experiments. One-tailed t-tests *P <0.05, **P < 0.01 
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Figure 2.7. The CDK5-activated dynein-NudEL-LIS1 pathway affects lysosome and mitochondria distribution in live cells 
Representative images of cells in various backgrounds stained with DAPI and either LysotrackerYellow or MitotrackerRed (a)  
and quantification of lysosome (left) or mitochondria (right) distribution (b) Quantified data represent the mean  s.e.m. of n = 2 
independent experiments. One-tailed t-tests ***P <0.001, ****P < 0.0001 
     The CDK5 pathway contributes to lysosomal tug-of-war 
There is an ongoing controversy in the field about the extent to which opposite-
polarity motors engage in a tug-of-war, and if so, the importance of such events, and how 
such tug-of-war events are regulated. We had previously published that such tug-of-war 
events do not appear important for LD motion91; but others reported that tug-of-war 
events do occur for endosome and phagosomes92,93. Since lysosomes are similar to 
endosomes and phagosomes, in that they are all membrane-bound and involved in cellular 
degradation, we reasoned that perhaps tug-of-war events between kinesin and dynein 
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occur here too. Because the NudEL-CDK5-14-3-3 pathway improves dynein’s average 
force production and especially the duration of the force production under load, one might 
expect that the magnitude/duration of tug-of-wars would be decreased when dynein’s 
force production is impaired. If one assumes that the plus-end and minus-end motors are 
randomly placed on the cargos, tug-of-wars should lead to cargo deformations. Thus, to test 
this possibility, Dr. Babu Reddy developed a new quantitative approach to measure 
lysosomal deformation in the time-lapse images by using custom written MATLAB code for 
image processing (see methods). We found that we could indeed detect numerous 
elongated lysosomes, and that the extent of such deformations was decreased in the CDK5 
knockdown background, consistent with a decrease in the magnitude of the tug-of-war 
events (Figure 2.8, Supplementary Figure 2.4). Thus, the data suggests that tug-of-war 
does occur between motors on the lysosomes, and that by tuning dynein’s function, the 
CDK5 pathway can tune the severity of the tug-of-wars. In principle, this change in 
apparent stretching could be simply due to decreased dynein utilization, however this 
appears unlikely because initial forces (reflecting the number of engaged motors before 
adaptation) were not significantly decreased in LDs from control vs CDK5 knockdown LDs 
(compare attempt 1 forces in Figure 2.1a and Figure 2.2a and Supplementary Figure 2.1), 
particle tracking found no difference in the overall number of moving lysosomes (not 
shown), or in the pause durations (Supplementary Figure 2.3a, b). Run lengths do appear 
slightly shorter in the CDK5 knockdown (Supplementary Figure 2.3c, d) in both travel 
directions. Interestingly, although decreased CDK5 activity diminishes the magnitude of 
tug-of-war events (as judged by the decreased magnitude of deformations), this change in 
tug-of-war properties did not appear to alter directional switching probabilities 
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(Supplementary Figure 2.3e), perhaps suggesting that the termination of a tug-of-war is 
regulated by a switching complex rather than load-induced stochastic disengagement of the 
dynein or kinesin motors. In conclusion, our data suggests that tug-of-war occurs for 
dynein-driven lysosomes, that the magnitude of severity of the tug-of-wars can be 
controlled via the CDK5 pathway, and that effect of such tug-of-wars on the properties of 
overall lysosomal motion is quite subtle. 
 
Figure 2.8. Lysosome deformation is reduced in CDK5 knockdown background 
Histogram of lysosome eccentricities in control cells (grey) and CDK5 knockdown cells (blue). Eccentricity of 0 is a perfect 
circle, and eccentricity of 1 reflects highly elongated lysosomes; note the increased frequency of large eccentricities (grey 
bars at 0.9, 0.95, 1) in the control relative to the CDK5 knockdown.  Distributions were determined to be very different 
(KS test, p < 0.0001) Quantified data represent n = 2 independent experiments 
 
Discussion  
Here, we investigated the regulation of dynein force production for LDs, 
mitochondria, and lysosomes; it is partly controlled by CDK5/14-3-3, with KIAA0528 also 
contributing to the first two. Overall, our data are consistent with a model where CDK5, 14-
3-3, and KIAA0528 are constitutively present on the cargo (Figure 2.3, Supplementary 
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Figure 2.6). Dynein force adaptation occurs when the presence of an obstacle induces 
CDK5 activation, and thus NudEL phosphorylation (which increases the affinity of NudEL 
for DIC86). This increased interaction facilitates a dynein-NudEL-LIS1 complex, with 
subsequent dynein force adaptation (as previously described in vitro11). Our work shows 
the importance of NudEL phosphorylation and the proteins involved—CDK5, 14-3-3, and 
KIAA0528: without these proteins, dynein can no longer increase its duration of force 
production, nor adapt its maximal forces. Consistent with this, alteration of the NudEL 
CDK5 phosphorylation sites alters the magnitude and duration of ensemble dynein force 
production (Figure 2.6).  
Our data suggest a two-step process for dynein force adaptation. First, our data 
show that force adaptation requires increased utilization of NudEL/LIS1; for such 
utilization to occur, NudEL must be phosphorylated at CDK5 phosphorylation sites, with 
14-3-3, and KIAA0528 contributing to control of this pathway. Second, before engaging 
NudEL, dynein is likely working with a different cofactor (“Cofactor 1”, likely dynactin); we 
believe that for successful force adaptation, Cofactor 1 must be released, in a CDK5-
independent manner (Figure 1). Such a hypothesis is consistent with all of our data to date. 
First, we note that in the CDK5 knockdown, or CDK5dn overexpression backgrounds, 
adaptation leads to increasing impairment of force production with successive attempts. 
We hypothesize that this reflects increasing release of Cofactor 1, without the ability to 
concurrently bind NudEL (due to its lack of phosphorylation); since we have blocked CDK5 
activity in these backgrounds, the Cofactor 1 release does not depend on CDK5 activity. 
Such a model is also consistent with the NudEL phospho-null and phospho-mimetic force 
measurements: we see increasing deterioration of duration of force production (in the 
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phospho-null case) and increasingly improved duration in the phospho-mimetic case, 
consistent with increasing release of Cofactor 1, paired with inability/ability to utilize 
NudEL phospho-null/phospho-mimetic. However, we do not see this decrease in forces and 
persistence times in the 14-3-3 knockdown nor the KIAA0528 knockdown. One 
interpretation of the finding in the 14-3-3 knockdown is that the key player CDK5 is still 
intact and can still phosphorylate NudEL, but the phosphorylation is more labile since 14-
3-3 levels are decreased enough that it cannot sufficiently protect the phosphorylations 
from the phosphatase PP2A. Similarly, in the KIAA0528 knockdown, we do not see any 
force adaptation, but there is no decrease in force or persistence times in subsequent 
attempts either. This might suggest another non-neuronal cofactor of CDK5 that is 
functionally redundant to KIAA0528; and so in the KIAA0528 knockdown, you still have 
enough phosphorylated NudEL that force and persistence times do not decrease and 
instead remain level. 
Our hypothesis about modulation of Cofactor 1’s involvement obviously raises 
questions about the role of dynactin in the force adaptation process. Dynactin (with BicD) 
is reported to improve dynein force production in vitro and in vivo59. If dynactin were 
playing a significant role here, one might have expected a significant drop in overall force 
production in the P150 KD background, which was not observed in our past study12. 
Instead, forces and persistence times adapted similarly to the wild-type12 (Reddy et al, 
2016 Figure 3a and c).  Overall, if there were simple competition between binding NudEL 
and dynactin controlled predominantly by the DIC-dynactin interaction, we would have 
expected altered (perhaps improved) adaptation in the P150 KD background, which did not 
occur. Thus, we favor a hypothesis in which here, dynactin is not contributing significantly 
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to dynein force production, and that adaptation requires both release of dynactin, and 
increasing utilization of NudEL controlled by phosphorylation. We note that our published 
data suggest that dynactin is somehow involved in adaptation: while its loss did not alter 
the magnitude or duration of force production, it did alter the time between force 
production events12 (Reddy et al, 2016 Figure 2h). Certainly, future work will need to 
investigate the control of dynactin utilization, and with this tool in hand, it may then be 
possible to unambiguously disentangle the coordinated sequence of events proposed 
above.   
Having determined that CDK5 does control force production for lipid droplets, we 
then established that it was a generalized pathway contributing to positioning control of 
other dynein cargos (Figure 2.7). We analyzed its contribution to lysosomal motion in 
more detail and found that lysosomal motors appear to engage in a tug-of-war, and that by 
altering dynein force production, CDK5 can tune the severity of such tug-of-war events 
(Figure 2.8). Interesting, we found that in the CDK5 knockdown background, the outcome 
of motor tug of wars is not changed. Since you would expect that in this background kinesin 
might likely be stronger than dynein, and therefore more often win the war (as exemplified 
by the cargo ultimately moving in the plus-end direction), but this was not the case. There 
seemed to be no bias in the outcome of the tug of war in either the control or the CDK5 
knockdown (Supplementary Figure 2.3e). We speculate that there is some other source 
of control acting as a traffic control for kinesins and dynein motors (that signals which 
motor to walk when) that we don’t yet understand. 
We also find that CDK5 knockdown results in slightly shorter plus-end and minus-
end runs (Supplementary Figure 2.3c, d). This finding is quite subtle but might account 
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for differences seen in the lysosome distributions in the CDK5 knockdown (Figure 2.7). As 
there has been shown to be coupling between motor activity (when one knockdowns 
dynein activity, sometimes kinesin activity decreases too), and such phenomenon could 
explain this result. Another possible interpretation is that because CDK5 is important for 
MT orientation in neurons, perhaps it is playing a role in orienting MTs in our experiments. 
If MTs disoriented, it is plausible that this signals kinesin and dynein cargo to not proceed 
with motion, resulting in shorter run lengths in both directions.  
Our findings have multiple implications. First, by directly measuring dynein cellular 
force production, and showing that CDK5 controls it in non-neuronal cells, we establish the 
CDK5 pathway as a validated mechano-control signaling pathway. Cells can thus locally 
increase ensemble dynein force production—one signature of which, for LDs, is force 
adaptation—as needed, via CDK5 activation.  
Second, assuming that these roles are indeed carried over into neurons, our data 
provide mechanistic insight into neuronal function, and how alteration of these specific 
proteins could lead to neuronal impairment. For instance, 14-3-3 is a schizophrenia risk 
factor, and our data suggest its loss will prevent dynein force production upregulation; 
thus, when evaluating candidate processes potentially altered by 14-3-3 decrease, one 
may want to focus on those requiring high forces, such as large cargo transport, MT 
reorientation, etc. Similarly, CDK5 was recently shown to play an important role in proper 
microtubule orientation in the axon initial segment (AIS)18. This new role for CDK5 in 
facilitating high-force events may help explain why this process requires CDK5, as changing 
MT orientation likely necessitates high dynein force production.   
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Third, the importance of upregulating dynein force production may vary locally. 
Cells typically have regional variations in the densities of organelles and cytoskeletal 
structures. For example, in COS-1 cells, the perinuclear region has higher densities than the 
cell periphery. Assuming cargos can engage multiple MTs simultaneously, these differences 
in cytoskeletal architecture may mean that force adaptation becomes important as dynein 
cargos approach the nucleus. In axons, dynein and its cargo may encounter blocks such as 
protein aggregates or stalled organelles, and there are regions that appear to have higher 
organelle and cytoskeletal density, including axonal branch points and AISs. In AISs, “actin 
patches” are thought to halt vesicles carrying dendritic proteins94, which may involve force 
adaptation allowing dynein to overpower kinesin plus-end motors in these patches. Local 
initiation of dynein force adaptation as motors encounter high density cytoplasm may thus 
be a critical role for the CDK5/14-3-3 pathway.  
Fourth, our data provide an intriguing framework for interpreting a previous report, 
which found that increasing neuronal CDK5 activity (via expression of its activator, P25) 
increased the number of stalled lysosomes17. Since we found that lysosomal-bound motors 
engage in moderate tug-of-war under normal conditions, and that the severity of those tug-
of-war events is controlled by CDK5 activity, it seems likely that tuning CDK5 activity could 
control dynein properties to avoid severe tug-of-war. This allows lysosomes to avoid 
concomitant dramatic stalling, which has been reported to occur in unregulated 
competition between kinesin and yeast dynein95 (working with NudEL and LIS1, 
cytoplasmic dynein functions more like yeast dynein (in the sense that it has a slow 
detachment under load). Therefore, one interpretation of the above-mentioned neuronal 
experiments suggests that increased CDK5 activity results in slower dynein detachment 
45 
 
under load, and even more severe tug-of-wars between lysosomal motors, resulting in 
increased numbers of stalled lysosomes. Further, this neuronal observation that increasing 
CDK5 activity leads to stalls—which we interpret as unresolved tug-of-war—provides an 
intriguing model for why control of CDK5 activity is so important, why its alteration may 
easily lead to problems, and why local force adaptation may be needed. If CDK5 is 
aberrantly active, dynein is too powerful, and competitions between dynein and kinesin 
cannot be well controlled. Thus, we hypothesize that dynein-mediated transport is tuned—
via CDK5 activity/14-3-3 levels and localization—to provide a moderately robust 
transport system with the ability to overcome typical obstacles to motion. We hypothesize 
that the role of force adaptation, then, is to prevent dynein from being too strong, so that 
tug-of-war typically resolves without aggravated traffic jams; it is only after repeated stalls 
(indicating a significant barrier) that maximum adaptation engages, subsequently allowing 
for increased dynein performance.  
Fifth, for bi-directionally moving cargos, there is typically tight coupling between 
plus-end and minus-end motor activity96,97: when one up- or down-regulates one set of 
motors, there is usually feedback (though unknown mechanisms) resulting in concomitant 
changes in the opposite-direction. Interestingly, CDK5 modulation of dynein force 
production appears to predominantly bypass such feedback: while the slight change in 
minus-end travel distances in the lysosomes is matched by plus-end changes 
(Supplementary Figure 3c, d), there is no such matching of effects on force production. 
Because the underlying mechanism contributing to force feedback matching opposite 
directions is unknown, we do not understand why such feedback fails here. However, this 
decoupling may be functionally useful allowing for selective directional control. In the wild-
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type force adaptation, minus-end forces and durations increase with attempt number, but 
plus-end ones stay constant. In the CDK5 knockdown/dominant-negative overexpression 
backgrounds, minus-end forces and durations decrease, but plus-end forces and durations 
remain unchanged (Supplementary Figure 2.2). Thus, at least for the cargos/cells 
considered here, the CDK5 pathway appears to almost entirely affect only minus-end motor 
activity, and allows for selective directional force production control.   
Finally, our findings may have implications for diabetes. LD biology is linked to 
insulin resistance98, and their transport directly affects metabolism7, so alteration in their 
trafficking by changes in force adaptation could potentially impact metabolic disease. 
Insulin signaling can regulate dynein to influence lysosome motility in both neurons and 
non-neuronal cells99. This involves inhibition of GSK-3β, a kinase whose dysregulation is 
linked to both metabolic and neurological disorders100. GSK-3β phosphorylation of dynein 
reduces its interaction with NudEL99. CDK5 can inhibit GSK-3β, but to our knowledge the 
opposite has not yet been reported101. Nonetheless, it will be interesting to determine if 
GSK-3β modulates force adaptation, and if so, if this occurs through altered NudEL 
phosphorylation by CDK5. Dynein is also required for internalization of adipocyte GLUT4 
receptors in low insulin conditions22. Dynein force adaptation could also modulate vesicle 
internalization. If that is the case, alterations in force adaptation mechanisms could lead to 
defective glucose transport. Interestingly, KIAA0528 may be involved in GLUT4 insertion 
into the plasma membrane, although this is not yet completely understood8,102.  
In summary, we found that NudEL phosphorylation control by the CDK5/14-3-3 
pathway directly regulates dynein force production in cells. It is required for the dynamic 
up-regulation of dynein force underlying the previously discovered LD force adaptation, 
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but also plays a general role for other cargos such as lysosomes and mitochondria, 
contributing to control of their subcellular localization. Further, the differential effects of 
KIAA0528 (affecting LDs and mitochondria, but not lysosomes) suggest cargo-specificity 
could in part be controlled by cargo-specific CDK5-interacting regulatory proteins like 
KIAA0528. Importantly, at least for lysosomes, the CDK5 pathway is able to tune dynein’s 
force production capability, and ultimately modulate motor tug-of-war severity; this likely 
seems relevant for various cellular cargos. Future work will undoubtedly explore 
ramifications of control of tug-of-war severity, the role and regulation of dynactin in this 
process, and how cargo-specific proteins like KIAA0528 mechanistically contribute to 
regulation.  
 
Materials and Methods 
Cell Culture and transfections. Mycoplasma-free COS-1 cells (obtained from ATCC) were 
grown in DMEM (Genesee) supplemented with 10% fetal bovine serum and 1% Pen-Strep 
at 37 C in 5% CO2. Gene expression knockdown for CDK5, 14-3-3, KIAA0528, NudE, and 
NudEL were completed by transient transfection using commercially available siRNAs. 
siRNA for the control (sc-37007), CDK5 (sc-29263), 14-3-3 (sc-29588), and KIAA0528 (sc-
95830) siRNAs were obtained from Santa Cruz Biotechnology. NudE (SI00655858, 
SI4374356, SI4341386, and SI05147835) and NudEL (SI03246600, SI03246936, 
SI04264379, and SI04321191) siRNAs were obtained from Qiagen.  
 For the CDK5, 14-3-3, KIAA0528, NudE, and NudEL knockdowns, HiPerfect reagent 
(Qiagen) was used following the manufacturer’s instructions. CDK5 and KIAA0528 
knockdowns were achieved by using a final concentration of 33nM siRNA; 14-3-3 
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knockdown was achieved by using a final concentration of 66nM siRNA; NudE and NudEL 
knockdowns were achieved by using a final concentration of 5nM of each siRNA. (Control 
transfections used the same final concentration of scrambled siRNA as the target siRNA.)  
 For the CDK5dn overexpression and NudEL replacement, Lipofectamine-2000 
(ThermoFisher Scientific) was used following manufacturer’s instructions. 2 g of DNA was 
used for the overexpression and replacement experiments.   
 Transient knockdowns were incubated for 48 hours before force measurements, 
WB, IP, and tracking experiments were carried out. Transient overexpression or 
replacement experiments were incubated for 24 hours before force measurements, WB, 
and tracking experiments were carried out. NudEL replacement expression was induced 
with 20 nM doxycycline 18 hours before force measurements, WB, fluorescence, and 
tracking experiments were carried out.  
Expression vectors. The CMV-myc-CDK5dn, pEGFP-C1-NudEL(WT) and phospho-null 
mutant (1-5A) expression vectors were previously described19.  
Mutagenesis and Cloning. The NudEL-WT plasmid was mutagenized into a phospho-
mimetic mutant using site-directed mutagenesis via Multi-Site-Directed Mutagenesis 
QuikChange Lightning (Agilent) in two rounds of mutagenesis. In the first round, F1-F3 
primers were used; in the second round, P4-P5 primers were used (Table 2.1). CDK5 
phosphosites on NudEL 1-5 were replaced with aspartic acid. 
Table 2.1. Oligos used in phospho-mutagenesis 
Oligo Name DNA Sequence 5’-3’ 
GFP-NudEL_S197D_F1 GCA GAG GGA GTT AGT GGA TCG GTA CCA AAA CCA TTT GG 
GFP-NudEL_T219D_F2 CAG TCT AGA GTT GGA GAG TCA GGA GCC GAC TTT CTA 
GFP-NudEL_S242D_F3 GTT CCT TTG CCA ACA GGG TCA GCT GGC AAA GAA AGT GAT GC 
GFP_NudEL1-5D_mutagen2_P4 CCT AGC AGA GGG ATC TAG TGG ATC GGT ACC 
GFP_NudEL1-5D_mutagen2_P5 GGT ATA GCT TCC GGA TCA GGA AAA GTG TTC TCC GTT CC 
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The three NudEL plasmids (WT, 1-5A, and 1-5D) were further mutagenized to achieve 
RNAi-resistance. Two silent mutations were introduced in the middle of each of the four 
siRNA target sequences of the NudEL mRNA sequence (for a total of eight 
mutations/construct). The NudEL plasmids were mutagenized using site-directed 
mutagenesis via Multi-Site-Directed Mutagenesis QuikChange Lightning (Agilent) in two 
rounds of mutagenesis. F1-F3 primers (Table 2.1) were used in the first round; and then 
F4-F6 primers (Table 2.1) were used in the second round. 
Table 2.1. Oligos used in RNAi-resistance mutagenesis 
Oligo Name DNA Sequence 5’-3’ 
NudEL-RNAiResistant_F1 GGA GAA AGA GCA CCA ATA TGC ACA GAG C 
NudEL-RNAiResistant_F2 CTC AGT GTT AGA GGA TGA TTT AAG TCA GAC TCG CGC CAT TAA GG 
NudEL-RNAiResistant_F3 CAG TGG AAG TTG AGC AAA GGC TAA ACC 
NudEL-RNAiResistant_F4 GGA GAA GCT AGA ACA CCA ATA TGC ACA GAG C 
NudEL-RNAiResistant_F5 CTC AGT GTT AGA GGA CGA TTT AAG TCA GAC ACG CGC CAT TAA GG 
NudEL-RNAiResistant_F6 CAC TGG AAG ACT TTG AGC AGA GGC TAA ACC 
 
The three RNAi-resistant NudEL constructs were then subcloned into the expression 
pDONOR201 vector via Gateway Technology (Invitrogen). These were then recombined 
into the gateway-compatible doxycycline-inducible destination vector and contained a C-
terminal-S-FLAG-SBP (SFB) tag103. 
Table 2.2. Oligos used to insert NudEL into pDONOR201 
Oligo Name DNA Sequence 5’-3’ 
GFP-NudEL_RNAiR4_F GGG GAC AAG TTT GTA CAA AAA AGC AGG CTC CAT GGT GAG 
CAA GGG CGA GGA GCT GTT C 
GFP-NudEL_RNAiR4_BP_Rc GGG GAC CAC TTT GTA CAA GAA AGC TGG GTT TCA CAC ACT GAG 
AGG CAG CAT ACC CGG 
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Immunoblotting. Cells were washed with PBS and lysed using an ice cold 1% NP-40 buffer 
containing a 1X protease inhibitor cocktail (Roche) and the supernatant was collected. 
Proteins from the lysate were denatured using an SDS buffer and incubating at 70 C for 10 
min. The proteins were then separated in a 4-12% Bis-tris gel (Life Technologies) and 
transferred to a nitrocellulose membrane through a wet transfer method. The 
nitrocellulose was blocked with 5% non-fat milk in Tris buffered saline (TBS: blocking 
buffer) for 45 min at room temperature. Immunoblotting was completed with respective 
antibodies and blots were visualized with infrared detection on the Odyssey (Licor). 
Primary antibodies were diluted in blocking buffer with Tween20 at various 
concentrations (1:200-1:1000 v/v). Secondary antibodies were diluted in blocking buffer 
with Tween20 at 1:10000 v/v. Antibodies were purchased from: Cell Signaling 
Technologies 2506s (CDK5) and 9635s (14-3-3), Bethyl A301-469A-M (KIAA0528), 
ABClonal A5776 (NudEL), Bioss bs-5522R (pSer231NudEL), Developmental Studies 
Hybridoma Bank E7-s (Tubulin-), Life Technologies (goat anti-mouse IgG 680), and Li-cor 
(goat anti-rabbit IgG 800). Data shown here are representative of 2-3 separate 
experiments. Quantification was completed in Licor’s ImageStudio. Since there is potential 
cross-reactivity in the anti-NudEL WB shown in Figure 6e, only the bottom green band was 
considered for quantification (the top green band is likely NudE).  
Force measurements in cells. Previously described12,104. 
Lysosome Distribution and Particle Tracking. After 48 hours of incubation with 
transfection reagents, COS-1 cells were stained with NucBlue Live ReadyProbes Reagent 
(Life Technologies) and either 200 nM LysoTracker-Yellow or 200 nM MitoTracker-Red 
(Thermo Fisher Scientific) and incubated for 30 min before visualization. Live COS-1 cells 
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were visualized at University of California Irvine Optical Biology Core on the Zeiss LSM700 
confocal laser scanning microscope. At least thirty cells were imaged. The cell perimeter, 
nuclear perimeter, and respective intensities were measured for each fluorescent image 
using ImageJ. The perinuclear region was defined as 20% of the cytoplasm surrounding the 
nucleus. The cell periphery was defined at the other 80% of the cytoplasm. The intensity of 
the cell periphery was defined as the total cell intensity minus the intensity of the 
perinuclear region. The percent total cell intensity in the cell periphery was defined as (the 
intensity of the cell periphery/total cell intensity)*100 (previously described105). 
Lipid Droplet Immunofluorescence. Lipid droplets (LDs) were purified using a sucrose 
gradient as previously described12. Purified LDs were incubated overnight with primary 
antibodies to a final concentration of 1 g/ml in the buffer (80mM PIPES, 1mM MgCl2, 2mM 
EGTA, 1mg/ml casein) followed by 1 hour incubation with secondary antibody (0.02 
mg/ml) in the same buffer described above. Fluorescence imaging was carried out using 
EMCCD camera (quantEM 512, Photometrics) and a 488 nm excitation laser in semi-TIRF 
mode. Fluorescence signal integration time was fixed at 0.5 sec.  
Eccentricity and Run Distances of Lysosomes. Cells were incubated with 200nM of 
Lysotracker red DND-99 (Life Technologies) for 30 min in the medium used for tissue 
culture.  A sample chamber similar to the one adopted for force measurements was used to 
image the cells. Images were acquired in semi-TIRF mode at 10 fps using 568nm excitation 
laser and the quantEM 512 camera. Spatial resolution of the acquired images in the above 
setup is 60nm/pixel.  
Eccentricity of lysosomes in each movie frame was determined using custom Matlab code 
for image processing. One hundred consecutive images for each cell (18 cells in each 
52 
 
condition from two experimental replicates) were used for this analysis, because the 
deformations could be dynamic, and we wanted to catch them if they occurred; the 
distributions shown thus reflect instantaneous multiple determinations of each lysosome’s 
eccentricity. If a specific lysosome was visible in all 100 consecutive frames, and it were 
circular in the first fifty frames, and very stretched in the next fifty, it would have yielded 
50 eccentricity measurements that were 0, and 50 that were 1, all included in the 
histogram. Binary images were generated from the raw images, and the eccentricity and 
areas of individual lysosomes were measured (after appropriate filtering to reduce the 
background). Eccentricity values range from 0 to 1, with 0 corresponding to a perfect circle 
and 1 representing highly deformed objects. Only lysosomes with areas in the range of 8-
200 square pixels were considered.  
Particle tracking was carried out by custom softwares LVcorr and Marathon. LVcorr was 
used to generate long tracks (track length ~100 sec and 90 tracks from 18 cells in each 
condition) from the videos recorded above. Using tracks files from LVcorr as input, the 
parsing software Marathon was used to extract the pauses and run distances of lysosomes 
moving linearly in kinesin and dynein directions. 
Statistics. All graphs are mean and s.e.m. Statistical significance was determined by 
Student’s t-test, test of proportions, Kolmogorov–Smirnov, and Wilcoxon sign-ranked t-test. 
*P <0.05, **P < 0.01, ***P < 0.001, ****P<0.0001 
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CHAPTER 3: Conclusion 
Overview 
 The mechanism of regulation of dynein force adaptation was characterized in 
Chapter 2. While detailed in the motion of lipid droplets, we expanded our study to other 
dynein cargos including mitochondria and lysosomes in order to determine if this 
regulatory pathway was important for multiple classes of cargo. We found that CDK5 
knockdown altered the distribution of lysosomes and mitochondria. To further study this 
pathway in the context of lysosomes, we knocked down other proteins involved in 
regulating dynein force adaptation and conducted our lysosome particle tracking and 
eccentricity analyses. We find that knocking down 14-3-3, but not KIAA0528, resulted in a 
similar phenotype in lysosome motion (increased motion with decrease levels of the 
pathway protein) and surprisingly the opposite phenotype in lysosome shape. In the 14-3-
3 knockdown, lysosomes are more elliptical, which was in direct contrast to the 
eccentricity phenotype in the CDK5 knockdown background (where lysosomes were found 
to be more spherical). This Chapter also details future directions aiming to determine the 
importance and cellular function of dynein force adaptation currently being explored by 
the lab and speculate on possible biological roles for dynein force adaptation. 
 
Conclusion 
 The regulation of molecular motors remains elusive. However, I have presented 
here a number of discoveries we have made during my time in the lab. We have discovered 
that in vitro, the signaling kinase CK2 reactivates the mitotic kinesin Eg5, although the 
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importance of this regulation in vivo is unclear. We suspected it might be important for cell 
proliferation, but this is not the case (Figure 1.4).  
For most retrograde intracellular transport, cells rely on the molecular motor 
dynein (MAP1C, dynein-1)11,31. Proper dynein function is essential to eukaryotic cellular 
vitality, and therefore it is important to understand the mechanisms and regulation of 
dynein function. As stated, dynein can form two main complexes: dynein-dynactin-BicD or 
dynein-NudEL-LIS114,16,56–58. While dynein-dynactin-BicD is important for long travel 
distances16, high processivity, dynein-NudEL-LIS1 is used when high force production is 
required12. Chapter 2 showed how the utilization of NudEL-LIS1 complex is regulated by 
CDK5 and detailed other proteins involved in this kinase signaling pathway. Specifically, we 
proposed that when dynein experiences an opposition to motion, CDK5 becomes activated 
possibly with the help of KIAA0528, phosphorylates NudEL, these phosphosites are 
protected (from dephosphorylation by the phosphatase PP2A) by 14-3-3, and once NudEL 
is phosphorylated, the interactions between dynein and NudEL are increased, and 
ultimately dynein can adapt its forces.  
We found that variations of this pathway exist for multiple dynein cargos. CDK5, 14-
3-3, and KIAA0528 are all essential for dynein force adaptation in the lipid droplet system 
(Figures 2.2, 2.4, and 2.5). However, in simply looking at differences in distribution of 
lysosomes, only knocking down CDK5 or knocking down 14-3-3 show different 
distribution phenotypes. The KIAA0528 knockdown showed similar lysosome distribution 
as the control cells (Figure 2.7). For mitochondria, knockdown of CDK5, 14-3-3, or 
KIAA0528 show different distribution phenotypes than the control (Figure 2.7).  
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To further characterize the effect of this phosphorylation pathway on lysosome 
motion, we conducted lysosome particle tracking and eccentricity analysis in the CDK5 
knockdown background. We found that while overall motion was not dramatically different 
between the control and the CDK5 knockdown, there was a significant difference in 
lysosome eccentricity (Figure 2.8). We speculated that this might be due to a difference in 
motor tug-of-war. Opposing molecular motors like dynein and kinesin can engage in tug-of-
war, but the implications of cargo-specific tug-of-war in cells is less understood91–93. We 
suggested that in the CDK5 knockdown cells, dynein is not able to adapt its forces and 
therefore kinesin outcompetes dynein in lysosomal tug-of-wars resulting in less elliptical 
lysosomes in the knockdown cells. This advocates for the role of dynein force adaptation as 
a check point: to keep dynein from becoming too strong.  
 The recent continuation of this study shows interesting lysosomal motion and shape 
analysis results for 14-3-3 knockdown and the KIAA0528 knockdown backgrounds. In 
particular, knocking down 14-3-3 resulted in overabundance of lysosomal motion within 
the cell (similar to the increased motion in the CDK5 knockdown background in Chapter 2, 
data not shown). However, when we analyzed lysosomal eccentricity, we found that 
lysosomes were more elongated in the 14-3-3 knockdown background than in the control 
(Figure 3.1).  This was the opposite trend seen in the CDK5 knockdown background where 
the lysosomes were more spherical than the control (Figure 2.8). This suggests that there 
is interference from another 14-3-3 pathway involving molecular motors. It is known that 
14-3-3 creates a bridge between dynein and kinesin-73 that ultimately mediates spindle 
localization38. One possible explanation of these surprising eccentricity results is that when 
this 14-3-3-dynein-kinesin-37 complex is formed, one motor is inactivated and the other 
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remains active. If 14-3-3 is not there to form the complex, and ultimately regulate the 
activity of each motor, then each class of motor remains continually active, likely engages in 
tug-of-war events with oppositely directed motors, and this ultimately results in elongated 
lysosomes. In the KIAA0528 knockdown, we find that the overall motion (data not shown) 
and eccentricity distribution (Figure 3.1) is similar to that of the control. This is expected 
since we found that knocking down KIAA0528 did not change lysosomal distributions in 
Chapter 2 (Figure 2.7).  
 
Figure 3.1. Lysosome eccentricity differences as a result of 14-3-3 knockdown or KIAA0528 knockdown 
Histogram of lysosome eccentricities in control cells (grey), 14-3-3 knockdown cells (orange), and KIAA0528 knockdown 
cells (pink). Eccentricity of 0 is a perfect circle, and eccentricity of 1 reflects highly elongated lysosomes; Quantified data 
represent n = 2 independent experiments 
 
Possible Cell Functions of Dynein Force Adaptation 
 We have characterized the CDK5 pathway controlling dynein force adaptation and 
generalized its importance for many dynein cargos. However, we have only begun to 
explore the possible cellular function of dynein force adaptation. There are many cellular 
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locations that could elicit dynein force adaptation. For example, dynein cargo may 
encounter more opposition to motion in crowded areas of the cell: like the perinuclear 
region where there is a large concentration of organelles. It could be that this is where 
increased utilization of the NudEL-LIS1 system is important for dynein to move its cargo 
through a concentrated area. Another similar location would be in the axon initiation 
segment in neurons. This is a major hub for dendritic cargo sorting, and therefore also 
quite concentrated. Maintaining dynein motors in a high force state may be important for 
dynein to navigate cargo through these segments.  
 Similarly, there are many cellular processes in which dynein force adaptation is 
essential. For example, it has been shown that when LIS1 is inhibited large (but not small) 
axonal cargo becomes stuck106. It seems likely, then, that dynein uses the NudEL-LIS1 
system to move largo cargo up and down narrow axons. It would be interesting to rescue 
stuck cargo in a LIS1 knockdown with a photo-activatable P25 (the CDK5 activator) 
construct. Then one could locally activate CDK5 and ultimately increase utilization of the 
NudEL-LIS1 system locally to see if that resolves the molecular traffic jams.  
Dynein is also known to be important for GLUT-4 internalization88,107 and has been 
shown to transport endosomes in HeLa cells108. One can imagine that dynein needs to 
maintain a high force persistence state by utilizing the NudEL-LIS1 system in order to pull 
early endosomes in towards the center of the cell. To study if this is the case, we plan to 
first knockdown CDK5 in RAW cells (a macrophage cell line). We will then induce these 
cells to endocytose beads in the control and CDK5 knockdown backgrounds and perform 
force measurements and particle tracking analysis of the endocytosed beads in order to 
determine if this cellular process utilizes dynein force adaptation. Given that this is a 
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dynein-driven pathway, and one that likely involved high force production, it is likely for 
endocytosis to necessitate dynein force adaptation.  
 
Regulation of Transport 
 My work here has focused on understanding the regulation of both kinesin, 
specifically Eg5, and dynein motors. While many labs are working to understand the 
cellular processes that these motors are involved in, we have focused on understanding 
how these motors become activated or inactivated in order to carry out their biological 
functions. We suggest that motors are frequently in their inactive state, and upon certain 
signal transduction (i.e. for Eg5: activation by the signaling kinase CK2, or for dynein: 
phosphorylation of NudEL by the signaling kinase CDK5), the motor (or the motor function, 
in the case of dynein force adaptation) is switched on at the proper space/time. Since many 
motors are found on the vesicles they transport109, this theory is plausible.  
However, more work will undoubtedly need to be done to confirm this theory. 
Specifically, while we have considered the effect of other proteins on motor regulation in 
this work, the organization of motors on the cargo itself can play a regulatory role as well. 
This has recently been studied by our group and others109–111. For example, Monte Carlo 
simulations suggest that motors cluster together to carry large cargo along extensive 
distances (tens of microns) within the cell, which requires more engaged motors111. 
Furthermore, motors must navigate a complex 3D matrix of microtubules within the 
cytoskeleton of the cytoplasm. Our collaborators suggest computationally that the 
cytoskeleton itself also plays a regulatory role for molecular motors112. However, such 
studies are in their infancy and with the recent advances in high resolution microscopy, 
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will likely expand to in vivo studies in the near future. I expect that in cells, the regulation of 
transport happens collectively, as an effort between the motors, their cofactors, their 
cargos, and the obstacles that the cell cytoplasm introduces. As a field, we will gain an 
abundance of knowledge about the interplay of all these factors that come together to 
successfully regulate molecular motors in the context of a cell.  
 
Perspectives 
 Overall, this works provides a basis of signaling regulation for two different classes 
of motors: the mitotic kinesin, Eg5, and the retrograde motor, cytoplasmic dynein. Although 
the work in Chapter 1 did not lead to interesting findings in cell biology, it provided more 
detail on the regulation of Eg5 in vitro. The work in Chapter 2, however, was much more 
successful. I expect that this work will provide a strong foundation for future studies of the 
biological importance of dynein force adaptation. The lab is already exploring one possible 
application of force adaptation in endocytosis by conducting endocytosis assays in RAW 
cells (a mouse macrophage cell line) in control and CDK5 knockdown backgrounds. I 
hypothesize that when dynein force adaptation is abolished (through knockdown of CDK5), 
the lab will see defects in endocytosis. Such studies will showcase the importance for 
dynein force adaptation in cell biology and reveal a new area of study for future molecular 
motor research. 
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SUPPLEMENTARY FIGURES 
 
Supplementary Figure 2.1. Transfection reagent (control) does not affect dynein force adaptation 
Average minus-end peak forces (a) and persistence times (b) were similar between wildtype cells (darker grey in each 
panel) and wildtype cells treated with HiPerfect (lighter grey in each panel). Quantified data represent the mean  s.e.m. 
of n   5 independent experiments. * P <0.05, ** P <0.01, ***P <0.001, ****P < 0.0001 
 
Supplementary Figure 2.2. Plus-end forces and persistence times show no force adaptation under any conditions 
Average peak forces (a) and persistence times (b) from plus-end moving LD cargo do not increase at each attempt in WT, 
CDK5 knockdown, CDK5dn overexpression, 14-3-3 knockdown, and KIAA0528 knockdown backgrounds. Quantified data 
represent the mean  s.e.m. of n   4 independent experiments. Force and persistence times values at each attempt were 
compared via ANOVA within each sample. All p-values > 0.05  
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Supplementary Figure 2.3. Most aspects of lysosomal motion are not altered by changes in Tug-of-war severity 
Particle tracking analysis of lysosomes shows no pause duration profile differences between control cells (a) and CDK5 
knockdown cells (b), a small run length difference between control (four samples traces are included) (c) and CDK5 
knockdown (four samples traces are included) (d) but no effect on the relative difference between plus-end run lengths 
and minus-end run lengths, and no significant differences in directional changes after pausing (e). PpM: lysosome moving 
towards the plus-end of MT, pauses, then moves towards the minus-end of MT, 
MpM: lysosome moving towards the minus-end of MT, pauses, then moves towards the minus-end of MT, 
PpP: lysosome moving towards the plus-end of MT, pauses, then moves towards the plus-end of MT, 
MpP: lysosome moving towards the minus-end of MT, pauses, then moves towards the plus-end of MT 
n = 2 independent experiments for a-d; n = 1 for e 
 
Supplementary Figure 2.4. Absolute counts of lysosome eccentricities from Figure 8 also show a difference in 
distribution 
(Wilcoxon Sign-Ranked t-test p value 0.00014) 
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Supplementary Figure 2.5. Full WBs presented in main figures 
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Supplementary Figure 2.6. Representative LDs from immunofluorescence (Figure 2.5) 
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Supplementary Figure 2.7. Representative images from Lysotracker and Mitotracker experiments (Figure 2.7) 
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Supplementary Figure 2.8. Sample traces of force measurement experiments 
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